COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers ...

Schizophrenia is a severe neuropsychiatric disorder characterized by hallucinations, false beliefs about oneself or the world ...

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to ...

The population-based cohort study included electronic health record data from the Hong Kong Hospital Authority for more than 11,051 adults with schizophrenia. Participants had used clozapine (n = 1450 ...

Cobenfy, the first new schizophrenia drug in 50 years, offers early insights that could pave the way for more personalized psychosis treatment.

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

The Schizophrenia & Psychosis Action Alliance recently welcomed five new members to its Board of Directors. Port Washington resident Donna Taylor is one of the recently appointed board members. The ...

Check out these resources for more information about childhood schizophrenia. March 12, 2010— -- For almost eight months, "20/20" chronicled the lives of three families with kids that have ...

People with schizophrenia often have delusions: false beliefs about themselves or the world around them. The types of delusions in schizophrenia can vary, but persecutory delusions are the most common ...

Symptoms of schizophrenia, a serious mental disorder that can include hallucinations and delusions, vary greatly from person to person. One common group of schizophrenia symptoms that doesn’t always ...